Daewon Pharm (003220) Fair Value & Analysis
Healthcare · KR · Market cap 164B KRW (≈ $115M) · ISIN KR7003220001
What is Daewon Pharm really worth?
Below-average quality, trading 25% below our fair value of 10,761 KRW.
Strengths
Risks
For context
Fair value as of: Aug 13, 2026
From 10 valuation models · updated 22 days ago
Share price +7.9% over the past month.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The large discount to fair value meets weak quality (44/100). That raises the risk this is a value trap rather than a bargain.
- A fairly wide model range (6,311 KRW to 15,212 KRW) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range 7,300 KRW – 21,237 KRW · fair‑value band 6,311 KRW – 15,212 KRW · the 8,070 KRW price screens below the 10,761 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Daewon Pharm (003220) currently trades at 8,070 KRW, while our model-based Fair Value estimate is 10,761 KRW, implying the stock looks roughly 25.0% undervalued today. The Quality Score stands at 44/100 (below-average quality), in the Healthcare sector. Bull case: the DCF Models group reads highest at a median of 10,745 KRW per share, and 4 of the 9 models we run sit above the 8,070 KRW price. Bear case: the Multiples group reads lowest at 1,116 KRW, and 5 of the 9 models stay below the price. Evidence for this calculation is medium.
Over the trailing twelve months, Daewon Pharm generated revenue of 606B KRW at a net margin of −0.7%. Revenue grew 0.1% year over year. It earns a return on equity of −1.8%. Net debt stands at 151B KRW. Fundamentals as of Aug 13, 2026
Our scenario range runs from 6,311 KRW (bear case) to 15,212 KRW (bull case); at 8,070 KRW, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 41% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −45% fair-value upside, at 33%, 003220 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.
All 10 models by family
Widest divergence: DCF Models (10,745 KRW) versus Multiples (1,116 KRW). Highest evidence: 5Y EBITDA Exit (72).
Notify me when 003220 reaches fair value
Put 003220 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 43 · Market factors (momentum, volatility) 27
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Daewon Pharmaceutical Co., Ltd., a pharmaceutical company, manufactures and sells medicines and medical supplies in South Korea. It offers various medicines for circulatory, respiratory, antibiotic, chemotherapy, and psychoneurosis use.
Full company description
Daewon Pharmaceutical Co., Ltd., a pharmaceutical company, manufactures and sells medicines and medical supplies in South Korea. It offers various medicines for circulatory, respiratory, antibiotic, chemotherapy, and psychoneurosis use. The company's principal products include Oramin-F Soft Cap, a multivitamin product; Pelubi Tablet, a NSAID product for pain relief; Freefol-MCT Inj., a microemulsion propofol for the anti-exogenous infectious bacteria; Megex-I Susp, a medicine that supplements subalimentation of cancer patients; Trigel Susp, a therapy for gastritis and duodenal ulcer; and Renamezin Cap, a spherical carbonaceous adsorbent for chronic kidney disease. It also exports its products to approximately 40 countries primarily in Asia, Central and South America, the Middle East, CIS, and Africa. The company was founded in 1958 and is headquartered in Seoul, South Korea.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Daewon Pharm reported revenue of 605B KRW in FY2025 versus 354B KRW in FY2021, a compound +14.3%/yr. Reported net income was −1.4B KRW in FY2025.
Watch 003220: get an alert when its fair value changes →
Peer Group
Drug Manufacturers - Specialty & Generic · 612 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Strength profile in five axes (Snowflake)
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Merck KGaA MRK | €140.25 | €106.48 | −24% |
| Takeda Pharmaceutical Company TAK | $18.03 | $11.11 | −38% |
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥53.76 | ¥25.94 | −52% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,944 | ₹989.50 | −49% |
| Galderma Group GALD | CHF 178.55 | CHF 55.07 | −69% |
| Haleon plc HLN | $10.11 | $7.64 | −24% |
| Teva Pharmaceutical Industries Limited TEVA | $36.05 | $15.33 | −57% |
| Sandoz Group SDZ | CHF 70.66 | CHF 39.21 | −45% |
| Zoetis Inc ZTS | $77.10 | $104.88 | +36% |
| Hansoh Pharmaceutical Group 3692 | HK$35.12 | HK$16.18 | −54% |
Compare Daewon Pharm with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Daewon Pharm (003220) overvalued or undervalued?
What is the fair value of 003220?
What is the quality score of 003220?
What is the revenue of Daewon Pharm (003220)?
What is the net profit margin of 003220?
Does Daewon Pharm pay a dividend?
Watch Daewon Pharm in the live analysis
One click puts Daewon Pharm on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.